Recent Updates
Recently added Catalysts

SPM 907

Phase 3

Overactive Bladder | Small molecule | Nephrology |Pfizer, Inc.|Last Updated: Nov 24, 2008

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials2
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

SPM 907 · 5 trials · 2 indications

Phase 3 4Phase 2 1
NCT00220402Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder SyndromeOveractive Bladder Syndrome
COMPLETED- Analytics
NCT00220376Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder SyndromeOveractive Bladder Syndrome
COMPLETED- Analytics
NCT00220363A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder SyndromeOveractive Bladder Syndrome
COMPLETED- Analytics
NCT00138723Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder SyndromeOveractive Bladder
COMPLETED- Analytics
PHASE3COMPLETED
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome
Overactive Bladder Syndrome
NCT00220402-
Unlock trial analytics
PHASE3COMPLETED
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome
Overactive Bladder Syndrome
NCT00220376-
Unlock trial analytics
PHASE3COMPLETED
A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome
Overactive Bladder Syndrome
NCT00220363-
Unlock trial analytics
PHASE3COMPLETED
Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome
Overactive Bladder
NCT00138723-
Unlock trial analytics

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP

Interventions

NameTypeDescription
SPM 907DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Participated in SP583 Exclusion Criteria: * Failure to complete 12 week treatment with SPM 907

Countries:GermanyUnited States
Unlock Eligibility Criteria

Frequently asked questions about SPM 907

What is SPM 907 used for?

SPM 907 is an investigational small molecule being developed for the treatment of Overactive Bladder Syndrome and Overactive Bladder. It is currently in Phase 3 clinical development, though all listed trials have been completed.

Who makes SPM 907?

SPM 907 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.

What phase is SPM 907 in?

SPM 907 is in Phase 3 clinical development. The drug is investigational and has not been reported as approved by regulatory authorities. All three Phase 3 trials listed for SPM 907 have been completed.

What clinical trials is SPM 907 in?

SPM 907 has been studied in three completed Phase 3 trials: NCT00138723, NCT00220363, and NCT00220376. These trials investigated the efficacy, tolerability, and safety of the drug in subjects with Overactive Bladder Syndrome or Overactive Bladder.

Is SPM 907 the same as fesoterodine?

SPM 907 is also known as fesoterodine sustained release. Clinical trial titles refer to fesoterodine sustained release, indicating SPM 907 is the same compound as fesoterodine in a sustained release formulation.